...
首页> 外文期刊>British journal of ophthalmology >Correction of lower eyelid retraction in thyroid eye disease: a randomised controlled trial of retractor tenotomy with adjuvant antimetabolite versus scleral graft.
【24h】

Correction of lower eyelid retraction in thyroid eye disease: a randomised controlled trial of retractor tenotomy with adjuvant antimetabolite versus scleral graft.

机译:甲状腺眼疾病下眼睑回缩的矫正:牵拉性张开术联合辅助抗代谢药与巩膜移植术的随机对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/AIMS: Lower eyelid retraction in thyroid eye disease contributes to ocular discomfort and an unsightly appearance, especially if asymmetrical. The use of donor scleral grafts is effective in lengthening the lower eyelids but carries a risk of virus transmission. Other techniques, including those which do not use grafts, need to be compared with scleral grafts. Recurrent retraction is a recognised complication of thyroid eyelid surgery; therefore, the authors investigated the use of antimetabolites to reduce postoperative fibrosis. METHODS: In this prospective randomised controlled trial of 25 patients (35 eyelids), the use of donor sclera in 20 lower eyelids (13 patients) was compared with partial tenotomy of the anterior part of the lower eyelid retractors (ALER) with adjuvant peroperative antimetabolite in 15 lower eyelids (12 patients). A 5 minute peroperative application of either 5-fluorouracil (25 mg/ml) in nine lower eyelids (eight patients) or mitomycin C (0.2 mg/ml) in six lower eyelids (four patients) was used to focally inhibit fibroblasts. Follow up ranged from 3 to 18 months (mean 7.8). RESULTS: One month after surgery the results of both groups were similar. However, at 3 months after surgery the results of scleral grafting were better than tenotomy with antimetabolites: 3/12 patients (25%) treated with tenotomy and adjuvant antimetabolite required subsequent surgery using grafts for correction of recurrent retraction. There were no significant complications associated with the use of antimetabolites in the eyelid in the doses used in this study. CONCLUSIONS: This randomised prospective trial shows that donor scleral grafts were more effective in the long term than partial tenotomy with adjuvant antimetabolite in the correction of lower eyelid retraction associated with thyroid eye disease. The use of peroperative antimetabolites in the lower eyelid was safe.
机译:背景/目的:甲状腺眼疾病中的下眼睑收缩会导致眼部不适和难看的外观,尤其是在不对称的情况下。使用供体巩膜移植物可有效延长下眼睑,但存在病毒传播的风险。其他技术,包括不使用移植物的技术,需要与巩膜移植物进行比较。复发性牵开是甲状腺眼睑手术的公认并发症。因此,作者研究了抗代谢物在减少术后纤维化中的作用。方法:在这项25例患者(35个眼睑)的前瞻性随机对照试验中,比较了20例下眼睑(13例患者)中使用供体巩膜与下眼睑牵开器前部部分切断术(ALER)及辅助术中抗代谢药物的比较在15个下眼皮中(12例)。术中在9个下眼睑(8例患者)中使用5氟尿嘧啶(25 mg / ml)或在6个下眼睑(4例患者)中使用丝裂霉素C(0.2 mg / ml)5分钟的手术来局部抑制成纤维细胞。随访时间为3到18个月(平均7.8)。结果:术后一个月两组的结果相似。然而,在术后3个月,巩膜移植的结果优于使用抗代谢物的腱切术:3/12例接受腱切术和辅助抗代谢药治疗的患者(25%)需要随后的手术,使用移植物来纠正复发性牵缩。在这项研究中使用的剂量没有与眼睑抗代谢物的使用相关的重大并发症。结论:这项随机的前瞻性试验表明,长期使用供体巩膜移植术比部分筋膜切开术联合辅助抗代谢药能更有效地纠正与甲状腺眼病相关的下眼睑退缩。在下眼睑使用围手术期抗代谢物是安全的。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号